Skip to content

Aspen Neuroscience, Inc.

ASPE· Nasdaqapplied forFiled to go publicCIK 2124080

Pharmaceutical Preparations, SIC 2834 · Incorporated in Delaware

Filed
Oct 9, 2026
Pages
263
Underwriters
5

Road to listing

  1. Draft submittedMar 30 · DRSA first draft of the registration statement, sent to the SEC in confidence.0001193125-26-132031
  2. Draft amendedMay 12 · DRS/A0001193125-26-219770
  3. Draft amendedJun 10 · DRS/A0001193125-26-264239
  4. Filed in publicOct 9 · S-1The registration statement, public for the first time.0001193125-26-419104
  5. AmendedOct 22 · S-1/AThe registration statement, revised.0001193125-26-428300
  6. AmendedToday · S-1/AThe registration statement, revised.0001193125-26-431023
  7. RoadshowNot yet · FWPA company that filed drafts in confidence must file in public at least 15 days before its roadshow begins.
  8. EffectiveNot yet · EFFECTThe SEC declares the registration statement effective, and the shares can be sold.
  9. PricedNot yet · 424B4The final prospectus, with the price the shares sold at.
  10. First tradeNot yet · ASPEThe shares open on the exchange, and the desk covers the company in full.

The company sent the SEC 3 drafts in confidence over 193 days, then filed in public on October 9, 2026. The dashed stops are still to come.

Cash
Jun 30, 2026p. F-26
Total assets
Jun 30, 2026p. F-26Liabilities $22.54M

Reading

Balance sheet

As filed, in the prospectus’s own lines.

LineDec 31, 2024Dec 31, 2025Jun 30, 2026
Cash and cash equivalents
Marketable securities
Prepaid expenses and other current assets
Total current assets
Operating lease right-of-use assets
Property and equipment, net
Restricted cash
Other noncurrent assets
Total assets
Total liabilities——
Convertible preferred stock——
Accounts payable
Accrued expenses
Operating lease liabilities, current
Other current liabilities
Total current liabilities
Operating lease liabilities, noncurrent
Other noncurrent liabilities——
Series Seed convertible preferred stock
Series Seed-2 convertible preferred stock
Series A-1 convertible preferred stock
Series A-2 convertible preferred stock
Series B convertible preferred stock
Series C convertible preferred stock—
Common stock———
Additional paid-in capital
Accumulated other comprehensive (loss) income—
Accumulated other comprehensive income—
Accumulated deficit
Total stockholder’s (deficit) equity——
Total stockholders’ deficit
Total liabilities, convertible preferred stock and stockholders’ deficit
Cash, cash equivalents, and marketable securities——
Working capital——

Read from the prospectus’s tables, merged into one statement: the audited financial statements first, every other table checked against them.

From SEC EDGAR · Form S-1/A · 0001193125-26-431023 · filed October 26, 2026